RS3PE in association with dipeptidyl peptidase-4 inhibitor: Report of two cases

Diabetes Care

Volumn 35, Issue 2, 2012, Pages

  Yamauchi, Keishi ^a   Sato, Yuka ^b   Yamashita, Koh ^a   Funase, Yoshiko ^a   Kaneko, Taimei ^b   Hashimoto, Takao ^a   Aizawa, Toru ^a  

^a Aizawa Hospital   (Japan)

^b NAGANO RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; HEMOGLOBIN A1C; PREDNISOLONE; SITAGLIPTIN; VILDAGLIPTIN;

AGED; CASE REPORT; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; LETTER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING EDEMA; SYNOVITIS;

AGED; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EDEMA; FEMALE; HUMANS; MALE; SYNOVITIS;

EID: 84859092128     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1995     Document Type: Letter

References (5)

1. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985;254:2763-2767 (Pubitemid 16243296)
2. Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: anoverview. Clin Exp Rheumatol 2000;18(Suppl. 20):S53-S55
3. Mattern T, Scholz W, Feller AC, Flad HD, Ulmer AJ. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol 1991;33:737-748
4. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. April 2011 [Epub ahead of print]
5. Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011;34:e133